Details of the Drug

General Information of Drug (ID: DMGYK2N)

Drug Name
Tilsotolimod
Synonyms IMO-2125
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 3 [1]
Drug Type
Oligonucleotide
Sequence
TCGAACGTTCG
Cross-matching ID
DrugBank ID
DB16341
TTD ID
D6YD0X

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Toll-like receptor 9 (TLR9) TTSHG0T TLR9_HUMAN Agonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Melanoma
ICD Disease Classification 2C30
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Toll-like receptor 9 (TLR9) DTT TLR9 2.58E-01 -0.06 -0.17
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03445533) A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301) (ILLUMINATE-301). U.S. National Institutes of Health.
2 Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma. Cancer Discov. 2021 Mar 11;candisc.1546.2020.